REPL
Replimune Group Inc.
Company Overview
| Mkt Cap | $673.04M | Price | $2.57 |
| Volume | 4.56M | Change | -4.10% |
| P/E Ratio | -2.7 | Open | $2.65 |
| Revenue | -- | Prev Close | $2.68 |
| Net Income | $-247.3M | 52W Range | $1.50 - $13.24 |
| Div Yield | N/A | Target | $2.20 |
| Overall | 33 | Value | 60 |
| Quality | 13 | Technical | 27 |
No chart data available
About Replimune Group Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Latest News
Replimune Group (REPL) was downgraded to a Hold Rating at Leerink Partners
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | REPL | $2.57 | -4.1% | 4.56M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |